As of July 31, 2018, send out testing to Mayo Medical Laboratories for “Candida albicans Antibodies (IgG, IgA, IgM)” and “Candida Antigen Detection” will be discontinued.
Mayo Clinic discontinued these tests due to a lack of clinical significance and challenges with interpretation as compared to fungal culture. Candida antibodies are detected in 20-30% of healthy individuals while immunocompromised individuals at increased risk for systemic candidiasis have blunted antibody responses. Sensitivity of 62% and specificity of 53% have been reported when using antibody levels to diagnose candidiasis.
Diagnosis is best accomplished by culturing the site of infection. The following fungal culture orders are available: